Adimmune Past Earnings Performance
Past criteria checks 0/6
Adimmune has been growing earnings at an average annual rate of 24.8%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 15.6% per year.
Key information
24.8%
Earnings growth rate
36.1%
EPS growth rate
Biotechs Industry Growth | 12.2% |
Revenue growth rate | 15.6% |
Return on equity | -13.3% |
Net Margin | -35.8% |
Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Adimmune makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,785 | -640 | 837 | 297 |
30 Sep 23 | 1,810 | -165 | 532 | 348 |
30 Jun 23 | 1,924 | -9 | 453 | 343 |
31 Mar 23 | 2,369 | 277 | 516 | 342 |
31 Dec 22 | 2,252 | 291 | 451 | 346 |
30 Sep 22 | 2,613 | 525 | 452 | 294 |
30 Jun 22 | 2,279 | 267 | 413 | 265 |
31 Mar 22 | 1,840 | 58 | 320 | 294 |
31 Dec 21 | 1,794 | 43 | 350 | 321 |
30 Sep 21 | 1,670 | 989 | 394 | 410 |
30 Jun 21 | 1,534 | 988 | 368 | 443 |
31 Mar 21 | 1,509 | 1,008 | 346 | 404 |
31 Dec 20 | 1,869 | 1,241 | 311 | 338 |
30 Sep 20 | 1,675 | -21 | 236 | 252 |
30 Jun 20 | 1,564 | -71 | 229 | 223 |
31 Mar 20 | 1,607 | -101 | 241 | 225 |
31 Dec 19 | 1,300 | -281 | 231 | 236 |
30 Sep 19 | 1,079 | -616 | 234 | 224 |
30 Jun 19 | 887 | -733 | 242 | 232 |
31 Mar 19 | 812 | -637 | 226 | 209 |
31 Dec 18 | 822 | -618 | 225 | 206 |
30 Sep 18 | 627 | -564 | 217 | 196 |
30 Jun 18 | 538 | -670 | 202 | 178 |
31 Mar 18 | 558 | -742 | 216 | 220 |
31 Dec 17 | 563 | -760 | 222 | 222 |
30 Sep 17 | 648 | -670 | 224 | 227 |
30 Jun 17 | 576 | -687 | 255 | 225 |
31 Mar 17 | 637 | -643 | 248 | 190 |
31 Dec 16 | 607 | -595 | 239 | 165 |
30 Sep 16 | 437 | -717 | 261 | 175 |
30 Jun 16 | 392 | -779 | 238 | 192 |
31 Mar 16 | 308 | -767 | 243 | 178 |
31 Dec 15 | 291 | -761 | 242 | 205 |
30 Sep 15 | 312 | -655 | 206 | 240 |
30 Jun 15 | 270 | -714 | 202 | 223 |
31 Mar 15 | 503 | -605 | 202 | 238 |
31 Dec 14 | 481 | -614 | 204 | 239 |
30 Sep 14 | 473 | -569 | 238 | 246 |
30 Jun 14 | 532 | -426 | 247 | 246 |
31 Mar 14 | 413 | -584 | 217 | 220 |
31 Dec 13 | 414 | -600 | 210 | 189 |
30 Sep 13 | 429 | -596 | 156 | 147 |
30 Jun 13 | 389 | -628 | 129 | 140 |
Quality Earnings: 4142 is currently unprofitable.
Growing Profit Margin: 4142 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4142 is unprofitable, but has reduced losses over the past 5 years at a rate of 24.8% per year.
Accelerating Growth: Unable to compare 4142's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4142 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 4142 has a negative Return on Equity (-13.33%), as it is currently unprofitable.